Angiotensin II receptor blockers and nephropathy trials

Diabetes Care

Volumn 24, Issue 10, 2001, Pages 1834-1838

  Bloomgarden, Zachary T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; BIPHENYL DERIVATIVE; IRBESARTAN; LOSARTAN; TETRAZOLE DERIVATIVE; VASODILATOR AGENT;

ALBUMINURIA; ANIMAL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; CONFERENCE PAPER; DIABETIC NEPHROPATHY; DRUG ANTAGONISM; GENETICS; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

ALBUMINURIA; ANIMALS; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; KIDNEY FAILURE, CHRONIC; LOSARTAN; OBESITY; RECEPTORS, ANGIOTENSIN; TETRAZOLES; VASODILATOR AGENTS;

EID: 0035487694     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.24.10.1834     Document Type: Article

References (1)

1. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S: Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 134:629-636, 2001